JAAD Game Changers: Dupilumab shows long-term safety and efficacy in patients with moderate-to-severe atopic dermatitis enrolled in a phase 3 open-label extension study

被引：0
|
作者：
Wohltmann, Wendi E. [1 ]
机构：
[1] San Antonio Mil Med Ctr, Dermatol & Pathol, 1100 Wilford Hall Loop, Jbsa Lackland, TX 78236 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2024年 / 91卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：613 / 613
页数：1
相关论文
共 50 条
  • [41] Safety efficacy of open-label dupilumab in adult patients with moderate-to-severe atopic dermatitis: an analysis up to 3 years (LIBERTY AD OLE)
    Thaci, D.
    Deleuran, M.
    Bissonnette, R.
    Bouaziz, J. D.
    Sun, X.
    Patel, N.
    Shumel, B.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E94 - E94
  • [42] Safety and Efficacy of Open-Label Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: An Analysis up to 3 Years (LIBERTY AD OLE)
    Thaci, Diamant
    Deleuran, Mette
    Bissonnette, Robert
    Bouaziz, Jean-David
    Sun, Xian
    Shumel, Brad
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 25 - 26
  • [43] Efficacy and safety of long-term treatment with dupilumab for moderate to severe atopic dermatitis
    Ikeda, M.
    Uehara, H.
    Tsuge, M.
    ALLERGY, 2019, 74 : 182 - 182
  • [44] Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Eichenfield, L. F.
    Blauvelt, A.
    Rosmarin, D.
    Hussain, I.
    Davis, J. D.
    Li, M.
    Zhang, Q.
    Gadkari, A.
    Eckert, L.
    Kamal, M. A.
    Bansal, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S104 - S104
  • [45] Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension
    Cork, M. J.
    Thaci, D.
    Eichenfield, L. F.
    Arkwright, P. D.
    Hultsch, T.
    Davis, J. D.
    Zhang, Y.
    Zhu, X.
    Chen, Z.
    Li, M.
    Ardeleanu, M.
    Teper, A.
    Akinlade, B.
    Gadkari, A.
    Eckert, L.
    Kamal, M. A.
    Ruddy, M.
    Graham, N. M. H.
    Pirozzi, G.
    Stahl, N.
    DiCioccio, A. T.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (01) : 85 - 96
  • [46] Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study
    Gooderham, Melinda J.
    Weidinger, Stephan
    Simpson, Eric L.
    Deleuran, Mette
    Gold, Linda F. Stein
    Farooqui, Saleem A.
    Biswas, Pinaki
    Chan, Gary
    Guler, Erman
    Koppensteiner, Herwig
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II32 - II33
  • [47] Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD)
    Cork, Michael J.
    Thaci, Diamant
    Eichenfield, Lawrence
    Arkwright, Peter D.
    Chen, Zhen
    Delevry, Dimittri
    O'Malley, John T.
    Bansal, Ashish
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB120 - AB120
  • [48] Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Lisa A. Beck
    Mette Deleuran
    Robert Bissonnette
    Marjolein de Bruin-Weller
    Ryszard Galus
    Takeshi Nakahara
    Seong Jun Seo
    Faisal A. Khokhar
    Jignesh Vakil
    Jing Xiao
    Ainara Rodriguez Marco
    Noah A. Levit
    John T. O’Malley
    Arsalan Shabbir
    American Journal of Clinical Dermatology, 2022, 23 : 393 - 408
  • [49] Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
    Beck, Lisa A.
    Deleuran, Mette
    Bissonnette, Robert
    de Bruin-Weller, Marjolein
    Galus, Ryszard
    Nakahara, Takeshi
    Seo, Seong Jun
    Khokhar, Faisal A.
    Vakil, Jignesh
    Xiao, Jing
    Marco, Ainara Rodriguez
    Levit, Noah A.
    O'Malley, John T.
    Shabbir, Arsalan
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (03) : 393 - 408
  • [50] Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
    Blauvelt, Andrew
    Langley, Richard G.
    Lacour, Jean-Philippe
    Toth, Darryl
    Laquer, Vivian
    Beissert, Stefan
    Wollenberg, Andreas
    Herranz, Pedro
    Pink, Andrew E.
    Peris, Ketty
    Fangel, Stine
    Gjerum, Le
    Corriveau, Joshua
    Saeki, Hidehisa
    Warren, Richard B.
    Simpson, Eric
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 815 - 824
12345